Comparing the current results to its competitors, Grifols Sa reported Revenue increase in the 4 quarter 2025 by 4.32 % year on year. The revenue growth was below Grifols Sa's competitors' average revenue growth of 7.01 %, achieved in the same quarter.
Grifols Sa's Comment on Competition and Industry Peers
The company expanded its Biopharma portfolio and competitive position through product launches and regulatory approvals, including the U.S. launch of Yimmugo, an intravenous immunoglobulin distributed by Kedrion Inc. The Diagnostics business unit introduced new immunohematology products, launched BTM middleware in the U.S., and received regulatory approval in China for the Eflexis blood typing platform. It also launched DC Scan Plus, a DG Gel test compliant with IVDR regulations. The Diagnostics unit filed multiple patents in molecular testing, infectious disease, blood typing, and clinical diagnostics, with a focus on blood typing platforms and developing tests for personalized medicine.
Overall company revenue, grew less, than total company revenues, at 4.32 % and company approximately market share, declined to 9.24 %. << More on GRFS Market Share.
*Market share is calculated based on total revenue.
April 4, 2024
Grifols Procleix ArboPlex Assay Revolutionizes Arbovirus Screening: First 4-in-1 NAT to Receive CE MarkBARCELONA, Spain - Grifols, a global leader in plasma-derived medicines and diagnostic solutions, has recently achieved a significant milestone in the field of arbovirus screening. The company announced that its groundbreaking Procleix ArboPlex Assay has obtained the CE mark under the In Vitro Diagnostic Regulation (IVDR). This accomplishment not only positions Grifols as the first to develop an automated nucleic acid test (NAT) specifically validated for screening blood donors, but it also represents the first ever NAT to detect four major arboviruses: chikungunya, dengue, West Nile, and Zika.Arboviruses, ...
February 14, 2024
Grifols, a renowned producer of plasma-derived medicines, has recently revealed positive topline results from its phase 3 clinical trial of BT524, a fibrinogen concentrate (FC) for the treatment of acquired fibrinogen deficiency (AFD). This development showcases the potential of BT524 to address an underserved growth market.Fibrinogen Deficiency and its Impact:Acquired Fibrinogen Deficiency (AFD) is a medical condition characterized by insufficient levels of fibrinogen, a vital blood plasma protein involved in blood clotting. Patients with AFD face an increased risk of bleeding and may experience prolonged bleeding following trauma or surgery. The lack of approved treatment options for AFD signifies a signif...
Sanofi's business model revolves around the development, production, and distribution of pharmaceutical products. They aim to innovate and provide healthcare solutions across various therapeutic areas to improve patients' lives worldwide. Sanofi collaborates with partners and healthcare professionals to ensure effective delivery of their products and to address evolving patient needs.
Xoma Corporation operates under a business model focused on the development and commercialization of novel therapeutics. The company primarily concentrates on creating antibody-based therapies to address unmet medical needs. Xoma also engages in collaborations and partnerships with other pharmaceutical companies to advance their product pipeline and expand their reach in the market.
Xenon Pharmaceuticals Inc operates in the biopharmaceutical industry, with a focus on discovering and developing innovative therapeutics. Their business model centers around leveraging their proprietary discovery platform to identify and advance potential drug candidates to address unmet medical needs. Through collaborations, licensing agreements, and internal development efforts, Xenon aims to bring new treatments to patients and create value for their stakeholders.
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
United Therapeutics Corporation's business model revolves around the development and commercialization of innovative therapeutics for treating rare diseases and chronic conditions. They focus on researching, manufacturing, marketing, and distributing their specialized pharmaceutical and medical products to healthcare providers and patients globally.
Sources:
Grifols Sa’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Grifols Sa versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
